PDS Biotechnology
Business Services · New Jersey, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
303 College Rd E Ste A, Princeton, New J...Phone Number
(800) 208-3343Website
www.pdsbiotech.comRevenue
$39.7 MillionStock Symbol
PDSBIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
3
1
1
1
About PDS Biotechnology
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies based on the Versamune platform. It provides developing novel investigational immunotherapies based on our T cell activating platforms to save and improve the lives of patients worldwide. The company was founded in 2005 and is headquartered in Princeton, New Jersey.Explore more
PDS Biotechnology Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is PDS Biotechnology your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once PDS Biotechnology has new funding data
Check if PDS Biotechnology has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at PDS Biotechnology
Check out if PDS Biotechnology is spiking on competitors!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when PDS Biotechnology launches new products
Earning: See what the market has to say on PDS Biotechnology recently announced quarterly report
Click to see if PDS Biotechnology had a recent Job posting/layoffs
PDS Biotechnology, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to PDS Biotechnology
Compare insights from companies similar to PDS Biotechnology, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
PDS Biotechnology is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
PDS Biotechnology is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about PDS Biotechnology.
PDS Biotechnology financials insights
Gather financial insights about PDS Biotechnology, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Debt
$902K
Private Equity
$1.1M
2021
Private Equity
$60M
Stock Offering
$52M
2022
Debt
$35M
PDS Biotechnology Tech Stack
A closer look at the technologies used by PDS Biotechnology
Most Recent Scoops
Project
PDS Biotechnology announced that all sites from the VERSATILE-002 trial will participate in the VERSATILE-003 study, with no sites lost during the protocol amendment pause, and that the company expects brisk patient recruitment given the sites' familiarity with the protocol and reduced competition in the space.
Clinical Operations
Project
PDS Biotechnology has been granted new patents for PDS0101 in the United States and Japan, with the new US patents combined with anticipated biologics exclusivity extending market protection into the 2040s, while the Japanese patent adds broad composition of matter claims to existing protections across major markets.
Intellectual Property, Legal Affairs
Earnings
PDS Biotechnology has reported net interest expense of $4.1 million for the year ended December 31, 2025, compared to $2.2 million for the year ended December 31, 2024, with the increase primarily attributable to non-cash expenses related to the extinguishment of debt and lower interest income on cash balances.
Earnings, Finance, Financing & Debt
Earnings
PDS Biotechnology has reported general and administrative expenses of $12.5 million for the year ended December 31, 2025, a decrease of $1.3 million compared to $13.8 million for the year ended December 31, 2024, primarily attributable to a decrease in personnel costs.
Earnings, Business Finance, Finance
Project
Medical Research, Clinical Operations
PDS Biotechnology News & Media
PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update
Investor Webcast Scheduled for 8:00 am ETPDS Biotech Announces Conference Call and Webcast for 2026 First Quarter Financial Results
PRINCETON, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call and webcast to report financial results for the quarter ended March 31, 2026, and will provide a clinical programs and corporate update, on Wednesday, May 13, 2026 at 8:00 am Eastern Time.PDS Biotech’s stock up on colorectal cancer trial success
PDS Biotech has released data from the Phase II investigator-led colorectal cancer trial.PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial
78% Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR 2-year survival rate of >80%; Parallel trial without PDS01ADC resulted in 2-year survival rate of ~35%
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding PDS Biotechnology
Sign Up For FreeTo access detailed company insights
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies based on the Versamune platform. It provides developing novel investigational immunotherapies based on our T cell activating platforms to save and improve the lives of patients worldwide. The company was founded... Read More
